Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Korea.
Cancer Res Treat. 2005 Oct;37(5):268-72. doi: 10.4143/crt.2005.37.5.268. Epub 2005 Oct 31.
We retrospectively analyzed the patients who received curative radiotherapy for unresectable stage III NSCLC to investigate the impact of chemotherapy.
From 1998 to 2001, the records of 224 patients who completed curative radiotherapy for NSCLC were reviewed. There were 210 males and 14 females, and their median age was 64 years (range 38 approximately 83). 54 patients had stage IIIA disease and 170 patients had stage IIIB disease. Conventional radiotherapy was given and the radiation dose ranged from 50 approximately 70 Gy with a median of 60 Gy, and chemotherapy was combined for 116 patients (52%).
The median survival, the 2-year, and 5-year actuarial survival rates of all 224 patients were 15 months, 30%, and 7%, respectively. The median survival of the patients with stage IIIA and IIIB disease were 21 months and 13 months, respectively (p=0.14). The median survival of patients who received chemoradiation was 18 months compared to 14 months for the patients who received RT alone (p=0.02). Among the chemoradiation group of patients, the median survival time of the patients who received 1 to 3 cycles of chemotherapy was 16 months and that for the patients who received more than 3 cycles was 22 months (p=0.07). We evaluated the effects of the timing of chemoradiation in 57 patients who received more than 3 cycles of chemotherapy. The median survival of the patients with the concurrent sequence was 25 months and that for the patients with the sequential chemotherapy was 19 months (p=0.81).
For advanced stage III non-small cell lung cancer patients who completed the curative radiotherapy, the addition of chemotherapy improved the survival compared to the patients who received radiotherapy alone.
我们回顾性分析了接受不可切除 III 期非小细胞肺癌（NSCLC）根治性放疗的患者，以探讨化疗的影响。
1998 年至 2001 年，我们对 224 例完成 NSCLC 根治性放疗的患者进行了回顾性分析。其中男性 210 例，女性 14 例，中位年龄 64 岁（范围 38-83 岁）。54 例为 IIIA 期疾病，170 例为 IIIB 期疾病。给予常规放疗，放疗剂量为 50-70Gy，中位剂量 60Gy，116 例（52%）联合化疗。
224 例患者的中位生存时间、2 年和 5 年生存率分别为 15 个月、30%和 7%。IIIA 期和 IIIB 期患者的中位生存时间分别为 21 个月和 13 个月（p=0.14）。放化疗组患者的中位生存时间为 18 个月，而单纯放疗组为 14 个月（p=0.02）。在放化疗组中，接受 1-3 个周期化疗的患者中位生存时间为 16 个月，接受超过 3 个周期化疗的患者中位生存时间为 22 个月（p=0.07）。我们评估了 57 例接受超过 3 个周期化疗的患者中放化疗时机的影响。同期放化疗患者的中位生存时间为 25 个月，序贯化疗患者的中位生存时间为 19 个月（p=0.81）。
对于完成根治性放疗的晚期 III 期非小细胞肺癌患者，与单纯放疗相比，联合化疗可提高生存。
